Compare
Natera, Inc. vs Fortrea Holdings Inc. vs Guardant Health, Inc. vs Caris Life Sciences, Inc.
| Latest fiscal year | Natera, Inc. NTRA | Fortrea Holdings Inc. FTRE | Guardant Health, Inc. GH | Caris Life Sciences, Inc. CAI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.31B | $2.72B | $982.02M | $812.03M |
| Revenue growth (YoY) | +35.9% | +1.0% | +32.9% | +97.0% |
| Gross margin | n/a | n/a | 64.5% (computed) | n/a |
| Operating margin | -13.4% | -32.0% | -44.5% | 5.6% |
| Net margin | -9.0% | -36.2% | -42.4% | -8.4% |
| Net income | -$208.16M | -$986.20M | -$416.28M | -$68.09M |
| EPS (Diluted) | -$1.52 | -$10.81 | -$3.32 | -$3.22 |
| Operating cash flow | $215.30M | $113.50M | -$184.76M | $83.16M |
| Free cash flow | $109.11M | $88.30M | -$233.07M | $66.89M |
| Cash & equivalents | n/a | $174.60M | $378.20M | $796.27M |
| Total assets | $2.40B | $2.72B | $2.01B | $1.13B |
| Total liabilities | $685.93M | $2.15B | $2.11B | $548.36M |
| Shareholders' equity | $1.71B | $563.50M | -$99.31M | $577.31M |
| Return on year-end equity | -12.2% | -175.0% | n/a | -11.8% |
| Shares outstanding | 139.69M | 93.10M | 130.64M | 282.53M |
Revenue, most recent five fiscal years
| Fiscal year | Natera, Inc. | Fortrea Holdings Inc. | Guardant Health, Inc. | Caris Life Sciences, Inc. |
|---|---|---|---|---|
| Latest | $2.31B Ended 2025-12-31 | $2.72B Ended 2025-12-31 | $982.02M Ended 2025-12-31 | $812.03M Ended 2025-12-31 |
| 1 year earlier | $1.70B Ended 2024-12-31 | $2.70B Ended 2024-12-31 | $739.02M Ended 2024-12-31 | $412.26M Ended 2024-12-31 |
| 2 years earlier | $1.08B Ended 2023-12-31 | $2.84B Ended 2023-12-31 | $563.95M Ended 2023-12-31 | $306.13M Ended 2023-12-31 |
| 3 years earlier | $820.22M Ended 2022-12-31 | $2.84B Ended 2022-12-31 | $449.54M Ended 2022-12-31 | n/a |
| 4 years earlier | $625.49M Ended 2021-12-31 | $3.06B Ended 2021-12-31 | $373.65M Ended 2021-12-31 | n/a |